<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>80(6)</volume><submitter>Matsubara N</submitter><journal>Cancer chemotherapy and pharmacology</journal><pagination>1073-1077</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6828099</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.</pubmed_title><pmcid>PMC6828099</pmcid><pubmed_authors>Hosono A</pubmed_authors><pubmed_authors>Sasaki M</pubmed_authors><pubmed_authors>Yajima Y</pubmed_authors><pubmed_authors>Yasuda M</pubmed_authors><pubmed_authors>Hashizume K</pubmed_authors><pubmed_authors>Matsubara N</pubmed_authors><pubmed_authors>Zurth C</pubmed_authors><pubmed_authors>Mukai H</pubmed_authors><pubmed_authors>Uemura M</pubmed_authors><pubmed_authors>Onomura M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.</name><description/><dates><release>2017-01-01T00:00:00Z</release><publication>2017 Dec</publication><modification>2025-04-22T17:38:07.904Z</modification><creation>2025-04-06T02:08:44.814Z</creation></dates><accession>S-EPMC6828099</accession><cross_references><pubmed>29063294</pubmed><doi>10.1007/s00280-017-3433-3</doi></cross_references></HashMap>